Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2017, Article ID 6257958, 11 pages
https://doi.org/10.1155/2017/6257958
Research Article

pVAXhsp65 Vaccination Primes for High IL-10 Production and Decreases Experimental Encephalomyelitis Severity

1Department of Microbiology and Immunology, Institute of Biosciences of Botucatu, Universidade Estadual Paulista (UNESP), Botucatu, SP, Brazil
2Flow Cytometry Laboratory, Amaral Carvalho Foundation, Jaú, SP, Brazil
3Department of Biochemistry and Immunology, University of São Paulo (USP), Ribeirão Preto, SP, Brazil

Correspondence should be addressed to Sofia Fernanda Gonçalves Zorzella-Pezavento; rb.moc.oohay@allezrozs

Received 9 November 2016; Revised 3 January 2017; Accepted 23 January 2017; Published 21 February 2017

Academic Editor: Alessandra Santos

Copyright © 2017 Sofia Fernanda Gonçalves Zorzella-Pezavento et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. M. Fletcher, S. J. Lalor, C. M. Sweeney, N. Tubridy, and K. H. G. Mills, “T cells in multiple sclerosis and experimental autoimmune encephalomyelitis,” Clinical and Experimental Immunology, vol. 162, no. 1, pp. 1–11, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. C. A. Dendrou, L. Fugger, and M. A. Friese, “Immunopathology of multiple sclerosis,” Nature Reviews Immunology, vol. 15, no. 9, pp. 545–558, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Steinman, “Assessment of animal models for MS and demyelinating disease in the design of rational therapy,” Neuron, vol. 24, no. 3, pp. 511–514, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. G. C. Furtado, M. C. G. Marcondes, J.-A. Latkowski, J. Tsai, A. Wensky, and J. J. Lafaille, “Swift entry of myelin-specific T lymphocytes into the central nervous system in spontaneous autoimmune encephalomyelitis,” Journal of Immunology, vol. 181, no. 7, pp. 4648–4655, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. R. A. O'Connor, C. T. Prendergast, C. A. Sabatos et al., “Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis,” Journal of Immunology, vol. 181, no. 6, pp. 3750–3754, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. W. I. McDonald and T. A. Sears, “The effects of experimental demyelination on conduction in the central nervous system,” Brain, vol. 93, no. 3, pp. 583–598, 1970. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Sanford, K. A. Lyseng-Williamson, E. G. Celius et al., “Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis,” Drugs, vol. 71, no. 14, pp. 1865–1891, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. K. P. Johnson, “Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis,” Expert Review of Neurotherapeutics, vol. 12, no. 4, pp. 371–384, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Waubant, “Overview of treatment options in multiple sclerosis,” Journal of Clinical Psychiatry, vol. 73, no. 6, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. I. M. Stromnes and J. M. Goverman, “Passive induction of experimental allergic encephalomyelitis,” Nature Protocols, vol. 1, no. 4, pp. 1952–1960, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Seger, S. F. G. Zorzella-Pezavento, A. C. Pelizon, D. R. Martins, A. Domingues, and A. Sartori, “Decreased production of TNF-alpha by lymph node cells indicates experimental autoimmune encephalomyelitis remission in Lewis rats,” Memorias do Instituto Oswaldo Cruz, vol. 105, no. 3, pp. 263–268, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. S. F. G. Zorzella-Pezavento, F. Chiuso-Minicucci, T. G. D. França et al., “Immunization with pVAXhsp65 decreases inflammation and modulates immune response in experimental encephalomyelitis,” NeuroImmunoModulation, vol. 17, no. 5, pp. 287–297, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Petermann and T. Korn, “Cytokines and effector T cell subsets causing autoimmune CNS disease,” FEBS Letters, vol. 585, no. 23, pp. 3747–3757, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. J. D. Fontenot, M. A. Gavin, and A. Y. Rudensky, “Foxp3 programs the development and function of CD4+CD25+ regulatory T cells,” Nature Immunology, vol. 4, no. 4, pp. 330–336, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Sakaguchi, N. Sakaguchi, M. Asano, M. Itoh, and M. Toda, “Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases,” Journal of Immunology, vol. 155, no. 3, pp. 1151–1164, 1995. View at Google Scholar · View at Scopus
  16. X. Yuan and T. R. Malek, “Cellular and molecular determinants for the development of natural and induced regulatory T cells,” Human Immunology, vol. 73, no. 8, pp. 773–782, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. M. G. Roncarolo, S. Gregori, M. Battaglia, R. Bacchetta, K. Fleischhauer, and M. K. Levings, “Interleukin-10-secreting type 1 regulatory T cells in rodents and humans,” Immunological Reviews, vol. 212, pp. 28–50, 2006. View at Google Scholar
  18. H. L. Weiner, “Induction and mechanism of action of transforming growth factor-β-secreting Th3 regulatory cells,” Immunological Reviews, vol. 182, pp. 207–214, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. I. Cortese, J. Ohayon, K. Fenton et al., “Cutaneous adverse events in multiple sclerosis patients treated with daclizumab,” Neurology, vol. 86, no. 9, pp. 847–855, 2016. View at Publisher · View at Google Scholar · View at Scopus
  20. W. Castro-Borrero, D. Graves, T. C. Frohman et al., “Current and emerging therapies in multiple sclerosis: a systematic review,” Therapeutic Advances in Neurological Disorders, vol. 5, no. 4, pp. 205–220, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Hegen, M. Auer, and F. Deisenhammer, “Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon-β,” Expert Opinion on Drug Metabolism and Toxicology, vol. 11, no. 12, pp. 1803–1819, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. D. M. Harrison and P. A. Calabresi, “Promising treatments of tomorrow for multiple sclerosis,” Annals of Indian Academy of Neurology, vol. 12, no. 4, pp. 283–290, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. A. H. Cross and R. T. Naismith, “Established and novel disease-modifying treatments in multiple sclerosis,” Journal of Internal Medicine, vol. 275, no. 4, pp. 350–363, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. W. Van Eden, G. Wick, S. Albani, and I. Cohen, “Stress, heat shock proteins, and autoimmunity: how immune responses to heat shock proteins are to be used for the control of chronic inflammatory diseases,” Annals of the New York Academy of Sciences, vol. 1113, pp. 217–237, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. C. L. Silva, V. L. D. Bonato, R. R. Dos Santos-Júnior, C. R. Zárate-Bladés, and A. Sartori, “Recent advances in DNA vaccines for autoimmune diseases,” Expert Review of Vaccines, vol. 8, no. 2, pp. 239–252, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Keijzer, L. Wieten, M. van Herwijnen, R. van der Zee, W. van Eden, and F. Broere, “Heat shock proteins are therapeutic targets in autoimmune diseases and other chronic inflammatory conditions,” Expert Opinion on Therapeutic Targets, vol. 16, no. 9, pp. 849–857, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Zhong, H. Tang, X. Wang et al., “Intranasal immunization with heat shock protein 60 induces CD4+CD25+GARP+ and type 1 regulatory T cells and inhibits early atherosclerosis,” Clinical and Experimental Immunology, vol. 183, no. 3, pp. 452–468, 2016. View at Publisher · View at Google Scholar · View at Scopus
  28. R. R. Santos-Junior, A. Sartori, M. De Franco et al., “Immunomodulation and protection induced by DNA-hsp65 vaccination in an animal model of arthritis,” Human Gene Therapy, vol. 16, no. 11, pp. 1338–1345, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. S. R. Satpute, R. Rajaiah, S. K. Polumuri, and K. D. Moudgil, “Tolerization with Hsp65 induces protection against adjuvant-induced arthritis by modulating the antigen-directed interferon-γ, interleukin-17, and antibody responses,” Arthritis and Rheumatism, vol. 60, no. 1, pp. 103–113, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Rodrigues Dos Santos Jr., A. Sartori, V. L. Deperon Bonato et al., “Immune modulation induced by tuberculosis DNA vaccine protects non-obese diabetic mice from diabetes progression,” Clinical and Experimental Immunology, vol. 149, no. 3, pp. 570–578, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. R. R. Santos, A. Sartori, D. S. Lima et al., “DNA vaccine containing the mycobacterial hsp65 gene prevented insulitis in MLD-STZ diabetes,” Journal of Immune Based Therapies and Vaccines, vol. 7, article no. 4, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. A.-H. Zhu, L. Jin, J.-J. Liu, M.-Y. Liu, A.-J. Lv, and Y.-L. Zheng, “Intranasal vaccination with mycobacterial 65-kD heat-shock protein can prevent insulitis and diabetes in non-obese diabetic mice,” Chinese Journal of Cellular and Molecular Immunology, vol. 27, no. 11, pp. 1165–1168, 2011. View at Google Scholar · View at Scopus
  33. C. Grundtman, B. Jakic, M. Buszko et al., “Mycobacterial heat shock protein 65 (mbHSP65)-induced atherosclerosis: preventive oral tolerization and definition of atheroprotective and atherogenic mbHSP65 peptides,” Atherosclerosis, vol. 242, no. 1, pp. 303–310, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. S. F. G. Zorzella-Pezavento, F. Chiuso-Minicucci, T. G. D. França et al., “Downmodulation of peripheral MOG-specific immunity by pVAXhsp65 treatment during EAE does not reach the CNS,” Journal of Neuroimmunology, vol. 268, no. 1-2, pp. 35–42, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. A. R. O. Watson and W. T. Lee, “Differences in signaling molecule organization between naive and memory CD4+ T lymphocytes,” Journal of Immunology, vol. 173, no. 1, pp. 33–41, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. S. A. dos Santos, C. R. Zárate-Bladés, F. C. de Sá Galetti et al., “A subunit vaccine based on biodegradable microspheres carrying rHsp65 protein and KLK protects BALB/c mice against tuberculosis infection,” Human Vaccines, vol. 6, no. 12, pp. 1047–1053, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. S. F. G. Zorzella-Pezavento, F. Chiuso-Minicucci, T. G. D. França et al., “Persistent inflammation in the CNS during chronic EAE despite local absence of IL-17 production,” Mediators of Inflammation, vol. 2013, Article ID 519627, 10 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. L. A. N. Mimura, F. Chiuso-Minicucci, T. F. C. Fraga-Silva et al., “Association of myelin peptide with vitamin D prevents autoimmune encephalomyelitis development,” Neuroscience, vol. 317, pp. 130–140, 2016. View at Publisher · View at Google Scholar · View at Scopus
  39. I. A. Soellner, J. Rabe, V. Mauri, J. Kaufmann, K. Addicks, and S. Kuerten, “Differential aspects of immune cell infiltration and neurodegeneration in acute and relapse experimental autoimmune encephalomyelitis,” Clinical Immunology, vol. 149, pp. 519–529, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. T. F. C. Fraga-Silva, L. A. N. Mimura, S. F. G. Zorzella-Pezavento et al., “Tolerogenic vaccination with MOG/VitD overcomes aggravating effect of C. albicans in experimental encephalomyelitis,” CNS Neuroscience & Therapeutics, vol. 22, no. 10, pp. 807–816, 2016. View at Publisher · View at Google Scholar · View at Scopus
  41. J. P. S. Peron, K. Yang, M.-L. Chen et al., “Oral tolerance reduces Th17 cells as well as the overall inflammation in the central nervous system of EAE mice,” Journal of Neuroimmunology, vol. 227, no. 1-2, pp. 10–17, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Li, Y. Li, X. Liu, X. Gao, and Y. Wang, “IL-33 blockade suppresses the development of experimental autoimmune encephalomyelitis in C57BL/6 mice,” Journal of Neuroimmunology, vol. 247, no. 1-2, pp. 25–31, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. F. Chiuso-Minicucci, L. L. W. Ishikawa, L. A. N. Mimura et al., “Treatment with vitamin D/MOG association suppresses experimental autoimmune encephalomyelitis,” PLoS ONE, vol. 10, no. 5, Article ID e0125836, 2015. View at Publisher · View at Google Scholar · View at Scopus
  44. F. Jadidi-Niaragh and A. Mirshafiey, “Regulatory T-cell as orchestra leader in immunosuppression process of multiple sclerosis,” Immunopharmacology and Immunotoxicology, vol. 33, no. 3, pp. 545–567, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. C. J. Workman, A. L. Szymczak-Workman, L. W. Collison, M. R. Pillai, and D. A. A. Vignali, “The development and function of regulatory T cells,” Cellular and Molecular Life Sciences, vol. 66, no. 16, pp. 2603–2622, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. P. A. Pino and A. E. Cardona, “Isolation of brain and spinal cord mononuclear cells using percoll gradients,” Journal of Visualized Experiments, no. 48, Article ID e2348, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. M. G. Harris and Z. Fabry, “Initiation and regulation of CNS autoimmunity: balancing immune surveillance and inflammation in the CNS,” Neuroscience & Medicine, vol. 3, no. 3, pp. 203–224, 2012. View at Publisher · View at Google Scholar
  48. J. M. Rodgers and S. D. Miller, “Cytokine control of inflammation and repair in the pathology of multiple sclerosis,” Yale Journal of Biology and Medicine, vol. 85, no. 4, pp. 447–468, 2012. View at Google Scholar · View at Scopus
  49. M. Cohen-Sfady, G. Nussbaum, M. Pevsner-Fischer et al., “Heat shock protein 60 activates B cells via the TLR4-MyD88 pathway,” Journal of Immunology, vol. 175, no. 6, pp. 3594–3602, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Zanin-Zhorov, G. Nussbaum, S. Franitza, I. R. Cohen, and O. Lider, “T cells respond to heat shock protein 60 via TLR2: activation of adhesion and inhibition of chemokine receptors,” The FASEB Journal, vol. 17, no. 11, pp. 1567–1569, 2003. View at Google Scholar · View at Scopus
  51. A. Zanin-Zhorov, L. Cahalon, G. Tal, R. Margalit, O. Lider, and I. R. Cohen, “Heat shock protein 60 enhances CD4+ CD25+ regulatory T cell function via innate TLR2 signaling,” Journal of Clinical Investigation, vol. 116, no. 7, pp. 2022–2032, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. S. B. Flohé, J. Brüggemann, S. Lendemans et al., “Human heat shock protein 60 induces maturation of dendritic cells versus a Th1-promoting phenotype,” Journal of Immunology, vol. 170, no. 5, pp. 2340–2348, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. I. C. Fontoura, A. P. F. Trombone, L. P. Almeida et al., “B cells expressing IL-10 mRNA modulate memory T cells after DNA-Hsp65 immunization,” Brazilian Journal of Medical and Biological Research, vol. 48, no. 12, pp. 1095–1100, 2015. View at Publisher · View at Google Scholar · View at Scopus
  54. Y. S. Shin, K. Takeda, Y. Shiraishi et al., “Microbial heat shock protein 65 attenuates airway hyperresponsiveness and inflammation by modulating the function of dendritic cells,” Journal of Immunology, vol. 189, no. 7, pp. 3404–3410, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. F. J. Quintana, A. Rotem, P. Carmi, and I. R. Cohen, “Vaccination with empty plasmid DNA or CpG oligonucleotide inhibits diabetes in nonobese diabetic mice: modulation of spontaneous 60-kDa heat shock protein autoimmunity,” The Journal of Immunology, vol. 165, no. 11, pp. 6148–6155, 2000. View at Publisher · View at Google Scholar · View at Scopus
  56. N. Fitzner, L. Zahner, C. Habich, and V. Kolb-Bachofen, “Stimulatory type A CpG-DNA induces a Th2-like response in human endothelial cells,” International Immunopharmacology, vol. 11, no. 11, pp. 1789–1795, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. L. C. Da Rosa, F. Chiuso-Minicucci, S. F. G. Zorzella-Pezavento et al., “Bacille Calmette-Guérin/DNAhsp65 prime-boost is protective against diabetes in non-obese diabetic mice but not in the streptozotocin model of type 1 diabetes,” Clinical and Experimental Immunology, vol. 173, no. 3, pp. 430–437, 2013. View at Publisher · View at Google Scholar · View at Scopus
  58. D. Harats, N. Yacov, B. Gilburd, Y. Shoenfeld, and J. George, “Oral tolerance with heat shock protein 65 attenuates Mycobacterium tuberculosis-induced and high-fat-diet-driven atherosclerotic lesions,” Journal of the American College of Cardiology, vol. 40, no. 7, pp. 1333–1338, 2002. View at Publisher · View at Google Scholar · View at Scopus
  59. F. J. Quintana and I. R. Cohen, “HSP60 speaks to the immune system in many voices,” Novartis Foundation Symposium, vol. 291, pp. 101–111, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. J. Liang, Z. Aihua, W. Yu, L. Yong, and L. Jingjing, “HSP65 serves as an immunogenic carrier for a diabetogenic peptide P277 inducing anti-inflammatory immune response in NOD mice by nasal administration,” Vaccine, vol. 28, no. 19, pp. 3312–3317, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. C. Rodríguez-Narciso, M. Pérez-Tapia, R. M. Rangel-Cano et al., “Expression of Mycobacterium leprae HSP65 in tobacco and its effectiveness as an oral treatment in adjuvant-induced arthritis,” Transgenic Research, vol. 20, no. 2, pp. 221–229, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. R. M. Rezende, R. P. Oliveira, S. R. Medeiros et al., “Hsp65-producing Lactococcus lactis prevents experimental autoimmune encephalomyelitis in mice by inducing CD4+LAP+ regulatory T cells,” Journal of Autoimmunity, vol. 40, no. 1, pp. 45–57, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. R. Billetta, N. Ghahramani, O. Morrow et al., “Epitope-specific immune tolerization ameliorates experimental autoimmune encephalomyelitis,” Clinical Immunology, vol. 145, no. 2, pp. 94–101, 2012. View at Publisher · View at Google Scholar · View at Scopus